InsidersTradesSigma
Track the A2M stock price and the full directors' dealings record of the company, a listed equity based in Australia. Shares trade on AU AU, under the supervision of ASX. Market capitalisation: €5.5bn. The latest transaction was reported on 25 June 2026 (Change in Substantial Holding). Among the most active insiders: Unknown Substantial Holder. The full history is openly available.
Analysts rate A2M Buy (bullish), based on 10 analysts. Average price target: A$8.06.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
A2M is a company listed on the XASX, specializing in the development of health products. It focuses on innovation in the healthcare sector.